Kyverna Therapeutics plans to submit cell therapy for stiff person syndrome for FDA approval If cleared, the medicine would be first personalized CAR-T therapy for an autoimmune disease

https://www.statnews.com/2026/04/21/kyverna-therapeutics-stiff-person-syndrome/ By Adam FeuersteinApril 21, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.